Szpital Specjalistyczny Im. Jedrzeja Sniadeckiego W Nowym Saczu
- Address
- Mlynska 5, 33-300 Nowy Sącz, Poland
Szpital Specjalistyczny Im. Jedrzeja Sniadeckiego W Nowym Saczu - Hematologic Malignancies Research
This specialized hospital in Nowy Sącz is actively engaged in cutting-edge clinical research focusing on hematologic malignancies, with particular expertise in the treatment of complex blood cancers. The center participates in international Phase III clinical trials investigating novel therapeutic approaches for patients with treatment-resistant disease.
- Relapsed or Refractory Multiple Myeloma (RRMM) treatment optimization
- Novel combination therapies including immunomodulatory agents and monoclonal antibodies
- Minimal residual disease (MRD) assessment and progression-free survival outcomes
The facility demonstrates significant commitment to advancing treatment options for patients with relapsed or refractory multiple myeloma, evaluating innovative therapeutic combinations such as iberdomide, daratumumab, and dexamethasone regimens. Their research focuses on comparing efficacy endpoints including MRD-negative complete response rates and progression-free survival, contributing valuable data to the global oncology research community and offering patients access to promising investigational therapies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 26 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Argenx1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Szpital Specjalistyczny Im. Jedrzeja Sniadeckiego W Nowym Saczu
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Efgartigimod Alfa in Adults with Primary Immune Thrombocytopenia: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study | Argenx | Phase III | Recruiting | Feb 2025 | — |
IMP list
lock Showing 1 of 26 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ruxolitinib | 3 | Unknown | 2020-07-24 | 2024-10-16 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.